Personalis Inc. Common Stock vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) — how do they compare? Personalis Inc. Common Stock trades at $16.14 (market cap $1.69B), while Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) trades at $7.68 (market cap $8.29B). The key difference: Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) is far larger — about 4.9× Personalis Inc. Common Stock's market cap, and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) pays a 4.82% dividend while Personalis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Personalis Inc. Common Stock for 0 Days and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) for 3 Days on average.
| PSNL | UGP | |
|---|---|---|
Market Cap | $1.69B | $8.29B |
Volume | 3,817,236 | 3,910,942 |
Sector | Health | Energy |
52-Week High | $18.38 | $7.90 |
52-Week Low | $5.04 | $3.63 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $1.52B | $10.36B |
Dividend Yield | — | 4.82% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UGP trades at $7.79, down 1.27% today but near recent 52-week highs. The stock shows strong technical momentum with bullish moving averages and solid fundamentals including 20.32% ROE and attractive valuation metrics (P/E 11.86, EV/EBITDA 5.1). Recent earnings beat expectations in Q2 2026 with $0.28 EPS versus $0.27 expected. The company demonstrated strong cash flow generation with $5.45B from operations in 2025, supporting its growth investments and financial discipline strategy outlined at recent investor events.
UGP presents a compelling value opportunity with improving profitability margins and revenue growth projected to reach $153.3B in 2026. However, risks include competitive pressures in oil and gas distribution, margin compression from rising costs, and dependence on energy price stability. Analyst consensus remains cautiously optimistic with 36% buy ratings but a $6.85 price target below current levels, suggesting potential near-term consolidation before further upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →Ultrapar is a Brazilian company with fuel distribution, liquefied petroleum gas, and chemical businesses. Its consumer-facing operations include fuel and gas distribution brands.
Read more on UGP →